What caused BLRX's Q1 2024 earnings to exceed forecasts?

BioLineRx Ltd. (BLRX) reported significant commercial progress for APHEXDA®, which contributed to the better-than-expected earnings in Q1 2024:

1. **Payer Coverage and Reimbursement**: BioLineRx secured payer coverage for approximately 95% of U.S. lives, facilitating Medicare reimbursement and ensuring broad accessibility for patients.
2. **Clinical Trial Progress**: The company initiated a Phase 2b clinical trial evaluating motixafortide in first-line pancreatic cancer, indicating continued innovation and potential for future revenue streams.

These factors, along with operational efficiencies, likely contributed to BLRX's improved financial performance.